Royal Bank of Canada’s Pfizer PFE Stock Holding History

Royal Bank of Canada’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$790M	Sell	32,814,260 -1,341,580	-4%	-$35.1M	0.12%	160
2026 Q1	$959M	Sell	34,155,840 -1,714,429	-5%	-$45.6M	0.17%	114
2025 Q4	$893M	Sell	35,870,269 -3,358,890	-9%	-$84.7M	0.15%	132
2025 Q3	$1,000M	Buy	39,229,159 +9,722,744	+33%	+$240M	0.16%	115
2025 Q2	$715M	Sell	29,506,415 -4,233,639	-13%	-$98.7M	0.13%	148
2025 Q1	$855M	Buy	33,740,054 +249,005	+0.7%	+$6.52M	0.18%	114
2024 Q4	$889M	Buy	33,491,049 +1,541,076	+5%	+$41.8M	0.18%	108
2024 Q3	$925M	Buy	31,949,973 +5,606,285	+21%	+$164M	0.19%	100
2024 Q2	$737M	Buy	26,343,688 +8,458,120	+47%	+$233M	0.17%	111
2024 Q1	$496M	Sell	17,885,568 -3,086,029	-15%	-$85.6M	0.11%	170
2023 Q4	$604M	Sell	20,971,597 -418,026	-2%	-$12.6M	0.14%	140
2023 Q3	$709M	Sell	21,389,623 -3,353,225	-14%	-$119M	0.19%	101
2023 Q2	$908M	Buy	24,742,848 +3,441,924	+16%	+$134M	0.24%	88
2023 Q1	$869M	Sell	21,300,924 -4,164,772	-16%	-$180M	0.25%	85
2022 Q4	$1.3B	Buy	25,465,696 +2,205,588	+9%	+$106M	0.37%	57
2022 Q3	$1.02B	Sell	23,260,108 -2,101,194	-8%	-$102M	0.32%	67
2022 Q2	$1.33B	Sell	25,361,302 -1,593,788	-6%	-$81.2M	0.39%	52
2022 Q1	$1.4B	Sell	26,955,090 -618,016	-2%	-$32.1M	0.35%	58
2021 Q4	$1.63B	Buy	27,573,106 +1,314,618	+5%	+$65.1M	0.37%	53
2021 Q3	$1.13B	Buy	26,258,488 +899,716	+4%	+$39.9M	0.3%	71
2021 Q2	$993M	Sell	25,358,772 -745,126	-3%	-$29M	0.26%	82
2021 Q1	$946M	Sell	26,103,898 -1,180,186	-4%	-$41.9M	0.27%	82
2020 Q4	$1B	Buy	27,284,084 +1,151,961	+4%	+$42.3M	0.29%	75
2020 Q3	$910M	Buy	26,132,123 +3,441,354	+15%	+$121M	0.32%	71
2020 Q2	$704M	Buy	22,690,769 +2,805,547	+14%	+$95.3M	0.28%	77
2020 Q1	$616M	Buy	19,885,222 +1,277,264	+7%	+$43.5M	0.3%	74
2019 Q4	$692M	Sell	18,607,958 -1,187,395	-6%	-$42.3M	0.25%	82
2019 Q3	$675M	Sell	19,795,353 -2,409,423	-11%	-$87.6M	0.27%	77
2019 Q2	$913M	Sell	22,204,776 -1,585,849	-7%	-$63M	0.37%	55
2019 Q1	$959M	Buy	23,790,625 +4,259,364	+22%	+$171M	0.41%	53
2018 Q4	$809M	Sell	19,531,261 -210,937	-1%	-$8.76M	0.39%	52
2018 Q3	$826M	Sell	19,742,198 -999,978	-5%	-$38.5M	0.34%	58
2018 Q2	$714M	Buy	20,742,176 +296,210	+1%	+$10.1M	0.32%	60
2018 Q1	$688M	Sell	20,445,966 -731,536	-3%	-$25.1M	0.31%	59
2017 Q4	$728M	Buy	21,177,502 +3,908,498	+23%	+$133M	0.32%	55
2017 Q3	$585M	Buy	17,269,004 +507,391	+3%	+$16.3M	0.28%	68
2017 Q2	$534M	Sell	16,761,613 -1,780,454	-10%	-$56.1M	0.28%	71
2017 Q1	$602M	Sell	18,542,067 -3,461,693	-16%	-$109M	0.32%	59
2016 Q4	$678M	Buy	22,003,760 +2,708,671	+14%	+$82.7M	0.37%	46
2016 Q3	$620M	Buy	19,295,089 +1,437,954	+8%	+$48.1M	0.35%	47
2016 Q2	$597M	Sell	17,857,135 -3,107,970	-15%	-$99.2M	0.36%	47
2016 Q1	$590M	Buy	20,965,105 +193,903	+0.9%	+$5.54M	0.37%	47
2015 Q4	$636M	Sell	20,771,202 -225,258	-1%	-$7.09M	0.42%	36
2015 Q3	$626M	Buy	20,996,460 +2,389,316	+13%	+$76.6M	0.47%	36
2015 Q2	$592M	Sell	18,607,144 -1,286,102	-6%	-$41.9M	0.41%	37
2015 Q1	$657M	Buy	19,893,246 +1,299,454	+7%	+$41.3M	0.46%	35
2014 Q4	$550M	Buy	18,593,792 +1,661,765	+10%	+$47.6M	0.36%	44
2014 Q3	$475M	Buy	16,932,027 +2,540,346	+18%	+$71.3M	0.32%	46
2014 Q2	$405M	Sell	14,391,681 -1,693,972	-11%	-$48.3M	0.27%	52
2014 Q1	$490M	Sell	16,085,653 -2,231,906	-12%	-$66.5M	0.36%	47
2013 Q4	$532M	Buy	18,317,559 +3,039,543	+20%	+$88.5M	0.38%	43
2013 Q3	$416M	Sell	15,278,016 -263,865	-2%	-$7.18M	0.32%	45
2013 Q2	$413M	Buy	+15,541,881	New	+$429M	0.35%	44

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Royal Bank of Canada's PFE Position: Q2 2026 in Review

Royal Bank of Canada reduced its Pfizer (PFE) stake by 3.9% in Q2 2026, selling an estimated $35.1M and leaving 32,814,260 shares worth $790M. The position accounts for 0.12% of the portfolio, ranked #160.

Royal Bank of Canada first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.63B in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Royal Bank of Canada held 32,814,260 shares of Pfizer worth $790M as of Q2 2026.
Royal Bank of Canada sold 1,341,580 Pfizer shares in Q2 2026, an estimated $35.1M.
Pfizer made up 0.12% of Royal Bank of Canada's portfolio in Q2 2026, its #160 holding.
Royal Bank of Canada first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Royal Bank of Canada's Pfizer position peaked at $1.63B in Q4 2021.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.